Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01174407

Enrollment

120

Registered

2010-08-03

Start date

2008-09-30

Completion date

2010-08-31

Last updated

2010-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Brief summary

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

Interventions

OTHERcd 35, cd21, cd55

Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Man and women over 18 years old * Filled out informed consent * Diagnosis of non-exudative/ exudative age related macular degeneneration

Exclusion criteria

* Inherited retinal diseases * Other acquired retinal/ macular * Missing informed consent

Design outcomes

Primary

Measure	Time frame
determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration	1 day

Secondary

Measure	Time frame
expression rates of on AMD-patients and a healthy control group	1 year

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026